| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_717aad3c62756ff5dd0fcfc69c8effb5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 |
| filingDate |
2000-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24ae7aad9f86fd27ec64b6f523b25a9a |
| publicationDate |
2001-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0100675-A1 |
| titleOfInvention |
Protamine-free insoluble acylated insulin compositions |
| abstract |
The present invention relates to ultralente-like crystals, comprised of insulin derivatives or insulin analog derivatives, and optionally, underivatized insulin or underivatized insulin analogs. Insoluble compositions comprising the ultralente-like crystals are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10040839-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9260503-B2 |
| priorityDate |
1999-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |